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Metabolic/Proteomic Signature 
Defines Two Glioblastoma Subtypes 
With Different Clinical Outcome
G. Marziali1,*, M. Signore1,*, M. Buccarelli1, S. Grande2, A. Palma2, M. Biffoni1, A. Rosi2, 
Q.G. D’Alessandris3, M. Martini4, L. M. Larocca4, R. De Maria5, R. Pallini3,† & L. Ricci-Vitiani1,†
Glioblastoma (GBM) is one of the deadliest human cancers. Because of the extremely unfavorable 
prognosis of GBM, it is important to develop more effective diagnostic and therapeutic strategies based 
on biologically and clinically relevant subclassification systems. Analyzing a collection of seventeen 
patient-derived glioblastoma stem-like cells (GSCs) by gene expression profiling, NMR spectroscopy 
and signal transduction pathway activation, we identified two GSC clusters, one characterized by a pro-
neural-like phenotype and the other showing a mesenchymal-like phenotype. Evaluating the levels of 
proteins differentially expressed by the two GSC clusters in the TCGA GBM sample collection, we found 
that SRC activation is associated with a GBM subgroup showing better prognosis whereas activation of 
RPS6, an effector of mTOR pathway, identifies a subgroup with a worse prognosis. The two clusters are 
also differentiated by NMR spectroscopy profiles suggesting a potential prognostic stratification based 
on metabolic evaluation. Our data show that the metabolic/proteomic profile of GSCs is informative of 
the genomic/proteomic GBM landscape, which differs among tumor subtypes and is associated with 
clinical outcome.
Glioblastoma multiforme (GBM) represents the most common and malignant brain tumor in adults, character-
ized by a high degree of cellular and genetic heterogeneity1. The overall prognosis of GBM patients remains poor 
with a median survival of 12–15 months2 despite multimodal therapy, including neurosurgical resection and 
radiotherapy with concomitant and adjuvant alkylating agent temozolomide. The clinical hallmarks of GBM that 
contribute to its awful prognosis are aggressive growth, limited response to therapy, and inexorable recurrence.
The emergence of molecularly focused approaches to cancer has fundamentally changed the path to diagnosis 
and treatment of malignancies. Histology is increasingly being supplemented with molecular analyses and these 
data subsequently inform therapeutic decision-making3.
In the framework of the The Cancer Genome Atlas (TCGA) a large panel of GBM samples have been analyzed 
at the combined genetic, epigenetic and proteomic level leading to the characterization of core tumorigenic path-
ways, identification of novel genes associated with the pathogenesis of GBM and classification into distinct, clini-
cally relevant molecular subtypes4–9. Genomic profiling defined four subtypes of GBM8, which were named based 
on the expression of signature genes as, i) proneural, highly enriched with the oligodendrocytic signature but 
not with the astrocytic signature; ii) neural, associated with oligodendrocytic and astrocytic differentiation and 
additionally enriched for genes expressed by neurons; iii) classical, strongly associated with the murine astrocytic 
signature; iv) mesenchymal, associated with the expression of mesenchymal and astrocytic markers4,10. Single cell 
RNA-seq shows that GBM assigned to a subtype based on tumor bulk analysis, present heterogeneous mixtures 
with individual cells corresponding to different glioblastoma subtypes and that the presence of heterogeneity of 
subtypes at the single cell level influences clinical outcome11.
Altogether these data show that “glioblastoma” is a heterogeneous collection of distinct diseases, with multiple 
pathway-dependencies both within and across each particular subtype.
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Growing evidences confirm that GBM contains a subpopulation of cells displaying stem-like properties remi-
niscent of normal stem cells, called tumor-initiating cells or GBM stem-like cells (GSCs) that are believed to play 
a fundamental role in tumor resistance to chemo- or radiotherapy and in recurrence12. GSCs can be isolated to 
generate cell lines characterized by self-renewing, multipotency, and highly tumorigenic ability and are reported 
to mirror both the genomic and the gene expression profiles of the original tumor more closely than conventional 
serum-cultured glioma cell lines13,14. Although the functional criteria defining GSCs are widely accepted, the 
molecular characteristics of these cells have not been fully identified12. As expected from the heterogeneous his-
tology of GBM, there is extensive cellular heterogeneity within GSCs as well11. The complex interplay of signaling 
pathways and the lack of common molecular markers identifying GSCs further complicate the analysis of these 
cells.
To further dissect the molecular biology of GBM and seeking for appropriate clinical targets to be exploited 
for drug treatment, we analyzed our collection of patient-derived GSCs by combining complementary molecular 
approaches. Taking into account the most variable genes/transcripts, gene expression profiling of GSCs revealed 
two distinct clusters. These clusters closely overlapped those obtained both from metabolic analysis by NMR 
spectroscopy and from signal transduction pathway activation, as assessed by reverse-phase protein microarray 
technology (RPPA). In addition, we analyzed available RPPA data from TCGA to evaluate the capability of pro-
teins differentially expressed in the two GSC clusters to predict patient survival.
Results
Gene expression profiling identifies two distinct phenotypes of GSC lines. Tumor samples from 
55 GBM patients were mechanically dissociated and cultured in stem cell medium. Seventeen of the 55 GBMs 
(31%) generated GSC lines. There were no significant differences between GSC-generating tumors and those 
tumors that did not generate GSC cultures relative to patient age and sex, symptom duration, and tumor location. 
Notably, median overall and progression free survival were significantly shorter in tumors that generated GSC 
cultures as compared with those that did not15. GSC lines were expanded and previously validated for their stem 
cell properties, such as the ability to self-renew, to generate progeny of multiple lineages in differentiating culture 
conditions and to phenocopy the patient tumor in mouse xenografts. In addition they were characterized for 
the expression of stem cell markers, including CD133 and SOX2, and for the presence of tumor-specific genetic 
changes15.
Gene expression data were collected from all the GSC lines and unsupervised hierarchical clustering of 
the samples using the 1,000 most variable genes/transcripts (below and above the interquartile range of the 
full dataset) produced two distinct GSC clusters (Fig. 1A), reminiscent of the separation into GSf (full stem) 
and GSr (restricted stem) phenotypes previously reported by Günther and colleagues, and by Schulte and col-
leagues16,17. The GSf phenotype is characterized by proneural-like gene expression signature, growth as floating 
spheres in vitro, CD133 expression, and high invasiveness in vivo. Conversely, GSCs with a GSr phenotype show 
mesenchymal-like expression signature, no CD133 expression, in vitro adherent growth, and low invasive behav-
ior in vivo16.
The 470 genes differentially regulated between our two GSC clusters (“GSC signature”, Supplementary Table S1a) 
were then subjected to a Gene Set Enrichment Analysis (GSEA)18,19. Chromosomal loci 19p13, 19p12 and, to 
a somewhat lesser extent, 19q13 were highly enriched in the GSC signature (Supplementary Table S1b). All 
these regions contain a large number of Krüppel-Type Zinc Finger proteins20. Region 19q13 has been reported 
as hypermethylated in oropharyngeal squamous cell carcinoma21 and copy-number-gain has been described 
in GBM22. The GSEA analysis also showed partial overlaps with mesenchymal, proneural and classical GBM 
sub-signatures established by Verhaak and colleagues8, an adult tissue stem-cell signature23, a stromal stem cell 
signature24 and oligodendrocyte differentiation25 (Supplementary Table S1c). Clustering of the GSC expression 
data using these partial gene lists (Fig. 1B) indicates a higher degree of “stemness” in the GSr-like lines coupled 
to a more mesenchymal-like phenotype. On the contrary GSf-like lines showed a more proneural/classical-like 
phenotype with reduced neural differentiation features and higher expression of regions 19p12 and 19p13. In line 
with this observation, proneural GBM has been recently proposed to arise from a non-stem-cell precursor, in 
contrast to the other three GBM subtypes26,27.
To further characterize our samples and compare them to previously described signatures, a large unified 
dataset was generated including data from both the Schulte GSf/GSr17 and the Verhaak TCGA GBM studies8. 
Genes/probes from the different microarray platforms were integrated through a batch correction procedure 
using only two global sample types, stem-cell or bulk tumor, i.e. without explicitly assigning a GSf or GSr pheno-
type to any sample. In the unified dataset, the GSC and GSf/GSr samples reproduce two homogeneous clusters 
with GSf(-like) or GSr(-like) phenotype, respectively (Fig. 1C), thus confirming the initial phenotype assignment 
of the GSC clones. Extending the analysis to include also the four subtypes of TCGA GBM samples and clustering 
by the Verhaak GBM subtype signatures, the GSr/GSr-like and GSf/GSf-like samples distinctly co-clustered with 
either the mesenchymal (M) or proneural (P)/classical (C) tumor subtypes, respectively (Supplementary Fig. S1a). 
Moreover, the overlap between the top 1000 most variable genes in GSf- vs GSr-like and the top 1000 most vari-
able genes in GSf/GSr combined dataset, showed that 609 genes are shared between GSf-/GSr-like and GSf/GSr 
(Supplementary Fig. S1b and Supplementary Table S1d). Interestingly, RNAseq analysis of 447 cancer-related 
genes on 167 TCGA GBM samples, shows a less stringent division between known subgroups when compared to 
the complete microarray panel (Supplementary Fig. S2).
1H NMR spectroscopy reveals two distinct metabolic phenotypes of GSCs. To identify pos-
sible metabolic phenotypes, the 17 GSC lines were assessed by 1D1H NMR spectroscopy. NMR spectra were 
acquired seven days after plating and were analyzed as previously described28 for the following metabolites: 
N-acetylaspartate (NAA), a neural marker involved in neurotransmitter production; γ -aminobutyric acid 
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(GABA), glutamate (Glu) and aspartate (Asp), which are major inhibitory or excitatory neurotransmitters in the 
brain; mobile lipids (MLs), often associated with cell death typical in brain malignancies29; myoinositol (Myo-I), 
related with the grade of brain tumors30; glutamine (Gln), related to the glial phenotype, and glutathione (GSH), 
an antioxidant regulator of ROS level31.
Clearly detectable signals of the astrocytic marker Myo-I and Gln were present in all GSC spectra, although 
with different signal intensities.
Unsupervised cluster analysis on the 17 GSC lines resulted in a dendrogram clearly separating the samples into 
two clusters (Fig. 2A). The first cluster, which is characterized by low lipids and high NAA and Gln, includes all 
GSf-like lines except the GSC line #112, whereas all GSr-like lines are grouped in the second cluster, characterized 
Figure 1. Gene expression analysis of 17 patient-derived GSCs identifies two distinct clusters.  
(A) Hierarchical clustering of GSCs using the top 1,000 most variable genes/probes in our gene expression 
datasets. (B) Hierarchical clustering of GSCs using a subset of the genes/probes in A, selected among the 
highest-score Gene Sets resulting from GSEA on genes/probes differentially regulated between Cluster 1 and 
Cluster 2. The colored left-side bar annotates the correspondent Gene Sets clusters. (C) Hierarchical clustering 
of the top 1,000 most variable common genes found in our GSC (yellow and brown rectangles) samples and in 
Schulte GSr/GSf (grey and black rectangles) samples. Heatmaps throughout the figure display differences in 
expression levels in log2 scale (red + 3, black = 0, green = − 3).
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by high lipids, low Gln and absent NAA. NAA signals were clearly observed only in GSf-like lines, indicating a 
metabolic fingerprint typical of neurons (Fig. 2B). These signals were barely detectable in GSr-like spectra, thus 
suggesting that the neuronal metabolism, although present, is not prevalent in these lines. The intensity of MLs 
signal was higher in GSr-like line spectra compared to GSf-like ones (Fig. 2B,C), indicating a prevalent astrocyte/
glioma-like metabolism. These two clusters closely superimpose those defined by gene expression analysis with 
the only exception of GSC line #112 (Fig. 2A), supporting an association of the GSf-like lines with the proneural 
subtype and of the GSr-like ones with the mesenchymal subtype.
Phosphoproteomic analysis confirms differential metabolic profiles in GSf-like and GSr-like 
cells. Genomic and transcriptomic analyses cannot fully account for the translational and post-translational 
integration of the complex genomic and transcriptomic aberrations accumulated in each tumor32–34. We recently 
demonstrated that reverse-phase protein array (RPPA) analysis identifies pathway activation patterns that cor-
relate with the response of GSCs to kinase inhibitors35. Therefore, we performed RPPA analysis on our collec-
tion of GSCs to measure the basal state levels of total and/or phosphorylated forms of diverse proteins involved 
in regulation of stemness, differentiation, migration, cell cycle, DNA damage, proliferation, cell growth, stress 
response and apoptosis (Supplementary Table S2). A comprehensive graphical representation and a list of the 
results of RPPA analysis on our GSC lines is available as Supplementary Fig. S3 and Supplementary Table S3, 
respectively. A pathway-oriented rather than single-endpoint approach to signaling analysis showed that GSf-like 
cells have a significant increase in SRC, Mitogen Activated Protein Kinase (MAPK), and Insulin-like Growth 
Factor- Receptor (IGF1-R/IR), whereas GSr-like lines displayed increased levels of phosphorylated proteins asso-
ciated with the mammalian Target of Rapamycin (mTOR) pathway (Fig. 3).
Figure 2. 1D1H NMR distinguishes two metabolic profiles of GSCs. (A) Unsupervised clustering of GSCs 
based on the levels of the analyzed metabolites. Samples are annotated with their matching gene expression 
clusters (colored boxes on the left) with the exception of sample #112. (B) GSr-/GSf-like ratios of NMR signal 
intensity means were converted to log2 and expressed as fold change (FC). Metabolites displaying a statistically 
significant (p < 0.05, Student’s t-test) difference between GSr- and GSf-like are indicated by asterisks.  
(C) Boxplots of raw NMR signal intensities of metabolites measured in GSf-like (cluster 1, yellow) and GSr-like 
(cluster 2, brown) samples.
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GSf- and GSr-like classification and clinical correlations. In a previous study, we demonstrated that 
the efficiency in establishing a GSC culture is about 30–40%, and that the capacity to generate GSCs represents an 
independent prognostic factor for poor patient survival15. Thus, we explored possible associations of the GSC sub-
types, i.e. GSf-like and GSr-like, with clinical and pathological parameters of the donor patients. Symptom dura-
tion prior to diagnosis was significantly shorter, indicative of a more aggressive clinical behaviour, in tumors that 
generated GSr-like cultures as compared with tumors generating GSf-like cultures (p = 0.0422; Mann-Whithey U 
test). In addition, a trend towards a worse general status, as assessed by the Karnofsky Performance Status score 
(KPS), was evident for tumors generating GSr-like cultures (p = 0.0529; Mann-Whithey U test). The median 
overall survival of the donor patients was 10.5 and 8 months for GSf-like and GSr-like tumors, respectively. No 
significant differences were found between GSf- and GSr-like generating tumors in terms of patient age or sex, 
tumor location or diameter, and extent of tumor resection (Supplementary Table S4). Among the molecular var-
iables, EGFRvIII expression was significantly more frequent in tumors generating GSr-like cultures than in those 
generating GSf-like cultures (p = 0.0345; Fisher exact test; Supplementary Table S5).
Analysis of GSf- and GSr-like molecular signatures in TCGA data. The most comprehensive 
(phospho-)proteomic characterization of GBM has recently been done under TCGA initiative, by Brennan and 
colleagues using RPPA9. We explored such data, comprising 181 protein analytes on 251 GBM samples, and 
found that unsupervised clustering failed to produce a consistent partitioning of the sample cohort into the 
four clearly-defined gene expression subtypes described by Verhaak and colleagues8, but rather grouped them 
into two dominant GBM subtypes (Supplementary Fig. S4). Thus, we asked whether the significantly different 
endpoints identified in GSf- and GSr-like GSCs by our RPPA analysis, could have prognostic value in the large 
cohort of GBM samples from TCGA. To this end, we used the Glioblastoma Bio Discovery Portal (GBM-BioDP, 
see methods section for details) and, as a query input, two gene symbol lists based on RPPA endpoints that 
Figure 3. Phosphoproteomic analysis supports genomic and metabolic clustering of GSCs. Boxplots of 
standardized levels of selected RPPA analytes displaying a statistically significant (p < 0.05, Wilcoxon rank 
sum test) difference between GSCs of GSr- or GSf-like gene expression cluster. Based on the absolute difference 
between RPPA levels measured in GSr- and GSf-like GSCs, endpoints were divided in two groups, i.e. GSr-like 
(brown, high in GSr-like) and GSf-like (yellow, high in GSf-like), respectively. RPPA endpoints are sorted in 
descending order starting from the one showing the highest levels in GSr-like GSCs. Each antibody is annotated 
(right side) with the corresponding p value. Outliers are shown as circles and names of the major pathways 
defining GSr- or GSf-like cells are reported for both clusters.
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were differentially expressed between GSf- and GSr-like GSCs (Supplementary Table S6 and methods section). 
Focusing on the proteins characterizing the GSf-like subgroup, we found that the levels of activated Human 
Epidermal Growth Factor Receptor 3 (HER3 pY1289) were higher in P versus M subtype (p = 0.00016, Fig. 4A) 
confirming a relationship between P and GSf subtypes. In addition, HER3 pY1289 was associated with longer 
overall survival in the global population (p = 0.01; Cox log rank test) (Fig. 5A and Supplementary Table 
S7). Phosphorylation of SRC at Y527 (SRC pY527) was significantly higher in P than in M GBM subtypes 
(p = 0.00031), whereas SRC pY416 was not different (Fig. 4A and Supplementary Table S7). Interestingly, despite 
a significant overall decrease in the levels of Focal Adhesion Kinase (FAK) in P versus M subtype (p = 0.00241), 
apparently challenging our RPPA data (Fig. 4A), FAK expression in TCGA data is significantly associated with 
poor prognosis only in P subtype (p = 0.0243; Cox log rank test, Supplementary Fig. S5a and Supplementary 
Table S7).
After single-endpoint analyses, we exploited the built-in feature of the GBM-BioDP platform to generate a 
multi-gene prognostic index (mPI) from RPPA data, including all GSf-like endpoints as covariates in a single 
Cox regression model (Fig. 5B). The resulting mPI (mPIGSf) was significantly associated with the outcome in 
both P and M subtypes (p = 0.000035 for the P subgroup and p = 0.000273 for the M subgroup; Cox log-rank 
test, Supplementary Fig. S6a), and also with the entire patient population (p = 0.000558; Cox log-rank test, 
Supplementary Fig. S6a) suggesting its potential unrestricted clinical relevance. Notably, levels of HER3 pY1289 
and SRC resulted as significant covariates (HR = 0.25, p = 0.0175 and HR = 0.14, p = 0.0394, respectively; Cox 
log-rank test), while FAK expression did not reach statistical significance (HR = 1.55, p = 0.0896; Cox log-rank 
test, Fig. 5B). Therefore, we used these three endpoints to build up a simplified mPIGSf model which, despite a lack 
of power in predicting outcome in the M subtype, was capable of predicting overall survival in the overall pop-
ulation (p = 0.002786; Cox log-rank test) and in the P subtype (p = 0.000207; Cox log-rank test, Supplementary 
Table S8 and Supplementary Fig. S7a).
Analyzing GBM TCGA patients using single GSr-like specific endpoints, we observed significantly higher lev-
els of phosphorylated Ribosomal Protein S6 (RPS6 pS235-36) in M versus P (p = 0.00761, Fig. 4B). Survival anal-
ysis showed that high RPS6 pS235-36 had a negative impact on survival, specifically in the P subtype (p = 0.0428; 
Cox log-rank test, Supplementary Fig. S5b and Supplementary Table S7). Notably, high levels of total and phos-
phorylated Eukaryotic initiation factor 4E binding protein 1 (4EBP1 and 4EBP1 pS65) were significantly associ-
ated with a better prognosis in the overall population of TCGA patients (p = 0.0489 and p = 0.0206, respectively; 
Cox log-rank test, Fig. 5C). High levels of 4EBP1 pS65 and two distinct phosphorylated forms of Epidermal 
Growth Factor Receptor (EGF-R pY1173 and EGF-R pY992) correlated with a better prognosis only in the P sub-
group, whereas high AKT pS473 was markedly associated with poor survival in the same subtype (Supplementary 
Fig. S5b and Supplementary Table S7).
Similarly to the GSf-like signature, to define a GSr-like mPI (mPIGSr), we computed a single Cox regression 
model with all the GSr-like-specific endpoints as covariates (Fig. 5D). Interestingly, we found that levels of RPS6 
pS235-36 inversely correlated with patient survival (HR = 9.12, p = 0.0082; Cox analysis, Fig. 5D) and that an 
increased overall survival was significantly predicted for all patients by the mPIGSr (p = 0.002019; Cox log-rank 
test, Supplementary Fig. S6b). Addition of age and MGMT status as covariates, significantly increased the capac-
ity of the mPIGSr to predict a worst outcome (p = 0.001965; Cox log-rank test, Supplementary Fig. 7B). In par-
ticular, the mPIGSr HR for the P subtype were 5.7 (p = 0.000073; Cox log-rank test) and 13.43 (p = 0.026878; 
Cox log-rank test) without and with age and MGMT status inclusion, respectively (Supplementary Fig. S6b and 
Supplementary Fig. S7b). Altogether these results indicate that the activation of two GSf-like endpoints, HER3 
and SRC, is associated with a GBM subgroup showing better prognosis whereas activation of RPS6, effector of 
mTOR pathway and GSr-like endpoint, identifies a subgroup with a worse prognosis.
Finally, based on the subset of GSr- and GSf-like RPPA endpoints which resulted significantly different among 
the two groups in previous analyses, we tested all possible binary combinations of such analytes that would better 
stratify TCGA patients into two groups with a significant survival difference. Notably, two specific expression 
patterns, i.e. i) elevated total SRC or SRC pY527 coupled to low RPS6 pS235-36 and ii) high RPS6 pS235-36 cou-
pled to low total SRC or SRC pY527, allowed us to discriminate two groups of TCGA patients: group with pattern 
i) displays a significantly better outcome than group with pattern ii) (Fig. 6). These results confirm the potential 
prognostic role of SRC and RPS6 in a large cohort of GBM patients.
Discussion
Glioblastomas are genetically heterogeneous tumors, suggesting that a diverse set of gene products may act to 
regulate their behavior and ultimately their outcome. Molecular classification of GBM is still at the beginning, and 
there is no general consensus on GBM subtypes. Despite several studies have provided a high resolution picture 
of GBM molecular landscape and revealed major alterations that may drive disease pathogenesis and biology, 
dependencies of tumors on altered signaling pathways suitable for direct translation to the clinics have not been 
yet identified and exploited in this tumor. The availability of GBM stem-like cell (GSC) line models reflecting gene 
expression patterns and phenotypic characteristics of human GBMs36 more closely than serum-cultured glioma 
cell lines, may help identifying cues for targeted therapies14. Although GSC cultures may represent a valuable 
tool for obtaining data to be translated onto the clinical setting, their translational power is still debated for at 
least two limiting factors. The first one is that, using our techniques, we arose GSC cultures from approximately 
one third of the tumors only. This implies that the GSC paradigm might not be applied in a substantial fraction 
of patients suffering from GBM but mainly to more aggressive cases, since median overall and progression free 
survival were significantly shorter in tumors that generated GSC cultures as compared with those that did not15. 
The second issue relates to cell heterogeneity of individual GBM11 and within individual GSC cultures, where 
mixed populations of GSCs and committed progenitors coexist, both capable of forming GSCs but where only 
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Figure 4. RPPA data from TCGA GBM samples. Boxplots of standardized levels of RPPA analytes measured 
in P (proneural, n = 41, pink) and M (mesemchymal, n = 29, red) samples selected from the full cohort 
(n = 214) of GBM tumors that was subjected to RPPA analysis within the TCGA consortium. The RPPA 
endpoints reported here were selected based on the presence, in the TCGA data, of analytes matching the GSf- 
(A, yellow box), or GSr-like (B, brown box) lists defined by our RPPA analysis (see methods sections for details). 
P values from unpaired t test are reported on top of each endpoint plot.
www.nature.com/scientificreports/
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GSCs are clonogenic37. Nonetheless, GSC cultures represent a valuable surrogate of their parental tumor and, 
although bearing intrinsic limitations, they allow molecular interrogation and study of one of deadliest tumors 
such as GBM.
In the attempt to find druggable signaling pathways in GBM, we analyzed a collection of 17 patient-derived 
GSCs by applying independent but complementary molecular approaches. Taking into account the potential bias 
of information obtained from our limited GSC samples, we compared our observations obtained on GSCs with 
datasets from large public databases annotated with clinical records. We were able to define two homogeneous 
subtypes resembling respectively the GSf and GSr groups described by Schulte, though with distinct molecular 
signatures.
Comparing genes differentially expressed between the GSf-like and the GSr-like GSC groups with gene sets 
from the literature, highly significant overlaps were present with two of the Verhaak GBM subtype signatures 
(mesenchymal and proneural), two stem-cell signatures23,24, and a gene set related to oligodendrocyte differen-
tiation25. The GSf-like and GSr-like clusters are characterized by a “pro-neural-like” and a “mesenchymal-like” 
expression signature, respectively. However, it should be emphasized that, comparing the molecular signature of 
our GSCs with that of GBM TCGA, which reflects the bulk tumor, may represent a limiting factor of this analysis.
Figure 5. GSf- and GSr-like RPPA endpoints ability to predict TCGA patient survival. Table plots of hazard 
ratios (HR) for expression levels of individual RPPA analytes, selected as distinctive of GSf- (A) and GSr-like 
(B) groups. For each RPPA endpoint, a Cox regression model was applied using the intensity levels (z score) 
and the subtyping as covariates. In order to generate a multi-gene prognostic index (mPI), the full selection of 
either GSf- (C) or GSr-like (D) RPPA analytes were included as covariates in a Cox model and table plots of 
corresponding hazard ratios are shown. Confidence intervals (95% CI) are reported for all HR together with 
logrank test p values and, for A and B, p values for the RPPA levels. The cohort of patients used for performing 
Cox survival analyses includes all TCGA patients with known Verhaak subtype (n = 111).
www.nature.com/scientificreports/
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Assessing more deeply the genes/transcripts that are differentially expressed between our GSf- and GSr-like 
lines, we found that genes located in chromosomal loci 19p13, 19p12, and 19q13 were highly enriched in the 
“GSC signature”. These regions contain a large number of Kruppel-type Zinc Finger transcription factors (ZNFs), 
which act mostly as chromatin modulating transcription repressor20. Several ZNFs have been identified as poten-
tial tumor suppressors and have often been found silenced in several tumor types. Deletions along chromosome 
19 are common events in several malignancies including ovarian38 cancer, esophageal squamous cell carcinoma39 
and oropharyngeal carcinoma21. The relevance of chromosome 19 alterations on the pathogenesis and prognosis 
of GBM deserves further evaluation.
To further investigate the signaling pathways differentially activated in GSf and GSr-like subgroups we per-
formed RPPA analysis. We found that GSf-like lines displayed a significant increase in activation of SRC, MAPK 
and IGF1R/IR pathways. Conversely, GSr-like lines showed increased levels of phosphorylated proteins associ-
ated with the EGFR and PI3K/mTOR pathways.
We then evaluated the expression levels of either GSf- or GSr-like RPPA endpoints in the large cohort of GBM 
samples from TCGA9 and compared them with the proneural and mesenchymal subtypes. Although our data on 
GSCs do not completely match previous RPPA analysis of TCGA GBM tumors, they confirmed the relevance of 
mTOR pathway in defining molecular subgroups of GBM.
A complete correlation between GSf-like and proneural or GSr-like and mesenchymal subtypes was not pres-
ent for all common RPPA endpoints, probably due to the different complexity of the systems (i.e. GBM tumors 
versus GSC lines) however, some of the RPPA analytes shared between TCGA and our data, displayed significant 
correlations with the clinical outcome of GBM patients. In particular, the GSf-like signature is characterized by 
the presence of active HER3, previously associated with CD133+ GBM stem cells40 and recently proposed as a 
potential target in GBM32. The GSf-like signature is also characterized by activation of proteins involved in the 
focal adhesion signaling axis, which is known to be driven by integrins, a hallmark of GBM stem cells41. The 
activation of HER3 and focal adhesion pathways confers a survival advantage to GBM patients in the TCGA 
cohort. This observation suggests that GSf-like GSCs might harbor phenotypical and molecular characteristics 
reminiscent of normal neural stem cells with migratory habit42. Conversely, the GSr-like signature is character-
ized by a strong activation of downstream targets of the EGFR and PI3K/mTOR pathway, which plays a crit-
ical role in cancer and, in particular, in GBM43. Interestingly, although the expression or activation of EGFR 
failed to correlate with the outcome in TCGA data, the presence of elevated levels of specific phosphorylation 
sites of both EGFR and RPS6, significantly associated with poor prognosis in the same cohort of GBM patients. 
Therefore, the GSr-like signature might be distinctive of a subset of metabolically active GSCs with high resistance 
Figure 6. Combined levels of phospho-SRC and phospho-RPS6 predict survival of TCGA GBM patients. 
GSf- (yellow) or GSr-like (brown) phenotypes were assigned to patients based on the combined expression 
of either SRC and RPS6 pS235-36 (A) or SRC pY527 and RPS6 pS235-36 (B) see methods section for details. 
Patients fulfilling the SRC/RPS6 pS235-36 median expression cut-off criterion were 58 per group while for the 
SRC pY527/RPS6 pS235-36 were 53 per group out of a total 211 TCGA patients analyzed. Log-rank p values, 
hazard ratio (with 95% confidence interval) and relative p values for the group variable are reported inside each 
plot.
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to chemo- and radio-therapy hence negatively influencing the survival of GBM patients. Indeed, when classifying 
TCGA patients based on combined expression patterns of the two RPPA endpoints typical of either the GSf- 
and GSr-like phenotype (i.e. SRC and RPS6, respectively), patients with GSr-like features display a significantly 
shorter overall survival. Despite the small sample size of our cohort, these results are in line with the clinical data 
of our patients producing lines of either GSf- or GSr-like groups.
Finally, the GSf-like and GSr-like clusters were clearly confirmed by NMR metabolic profiling. The GSf-like 
subtype, characterized by metabolites involved in the production of neurotransmitters such as NAA and GABA, 
is suggestive of a prevalent neuronal metabolism. The GSr-like subtype, characterized by lack of NAA and GABA 
and by high mobile lipids (MLs), is indicative of a prevalent astroglial-like metabolism. These metabolic profiles 
corroborate the association of the GSf-like group with the pro-neural GBM subtype resulting from independent 
gene expression analysis and with a different prognosis. In the clinical practice, NMR spectroscopy is mainly 
used to differentiate GBM from lower grade gliomas44. Hallmarks of GBM are high choline/NAA and choline/
creatinine ratios, and a lactate/lipid peak, which reflects tumor necrosis. Currently, NMR spectroscopy is not used 
to stratify GBM patients for prognostic purposes. In experimental settings, high glutamate signal has been cor-
related to IDH1 wild-type GBM45. In this study we showed that, at least in a subgroup of patients, the metabolic 
features of GBM cells, as assessed by NMR analysis, may be informative of the genomic/proteomic landscape of 
the tumor, and ultimately of the GBM subtype and clinical outcome. Finally, here we provide evidence that com-
bined measurement of levels of two proteins, namely phospho-SRC and phospho-RPS6, may be informative on 
the outcome of GBM patients. Further investigation with increased sample size could confirm our observations 
providing important information on the pathogenesis of human GBM and eventually leading to an improvement 
of GBM diagnosis and to an indication for most appropriate therapeutic strategy.
Methods
Patients, diagnosis, and tumor characterization. Tumor tissue samples were collected from adult 
patients with GBM tumors (WHO grade IV) undergoing complete or partial surgical resection at the Institute of 
Neurosurgery, Catholic University School of Medicine in Rome. Informed consent was obtained from the patients 
before surgery. Experimental protocols were approved by the ethical committee of the Catholic University of 
Rome. Experiments were performed according to the guidelines approved by ethical committees of the Istituto 
Superiore di Sanità and Catholic University of Rome. Clinical and pathological features are summarized in 
Supplementary Table S3.
The expression of the proliferation marker Ki-67 and of Phosphatase and Tensin Homolog (PTEN) 
were characterized on tumor specimen by immunohistochemistry on deparaffinized sections using the 
avidin-biotin-peroxidase complex methods (ABC-Elite kit, Vector Laboratories), anti-Ki67 monoclonal 
antibody (MIB-1, Dako) and anti-PTEN mouse monoclonal antibody (clone 28H6; Novo Castra, Newcastle, 
United Kingdom). O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation patterns were 
assessed on genomic DNA extracted from paraffin-embedded tissue by methylation-specific PCR as previously 
described15. Levels of VEGF and EGFRvIII were assessed as previously described46.
Establishing GSC cultures. GSCs were isolated through mechanical dissociation of the tumor tissue and 
cultured in a serum-free medium supplemented with epidermal growth factor and basic fibroblast growth factor 
as previously described15. Cell lines actively proliferating required 3 to 4 weeks to be established. In these condi-
tions, cells grow as clusters of undifferentiated cells, as indicated by morphology and expression of stem cell mark-
ers such as CD133, SOX2, Musashi-1, and nestin. The in vivo tumorigenic potential of GBM neurospheres was 
assayed by intracranial or subcutaneous cell injection in immunocompromised mice. GBM neurospheres were 
able to generate a tumor identical to the human tumor in antigen expression and histological tissue organization.
Gene expression profiling. For GSC gene expression data collection, total RNA was extracted, labe-
led and hybridized to the Affymetrix GeneChip1.0ST array (Affymetrix, Santa Clara, CA, USA) accord-
ing the manufacturer’s instructions. Data preprocessing prior to the formal statistical analysis involved 
standard processes of normalization [robust Multi-array Average (RMA) method]. All data analysis was performed 
with R (http://www.R-project.org) using Bioconductor47. Differentially regulated genes were determined with 
LIMMA48 applying default parameters and a FDR-corrected p value cutoff < 0.05.Generation of the unified 
dataset involved through two consecutive steps. After downloading the data from GEO (GSE23806)17, or the 
TCGA website (https://tcga-data.nci.nih.gov/docs/publications/gbm_exp/)8, equivalent “best” probes from 
the different microarray platforms (GSCs: Affymetrix Gene Chip 1.0S17, GSE23806: Affymetrix HG-U133 Plus 
2.08, data: LBL202 dataset Affymetrix HuExon) were selected based on the Affymetrix annotation files from the 
NetAffx website. The combined dataset comprised 15697 probes/genes. In a second step the ComBat batch cor-
rection algorithm49 was used to combine the three different datasets. GSC samples and GSr/GSf samples from 
GSE23806 were all assigned the same SC qualifier as the first covariate variable. Likewise GBM tumor samples 
from TCGA and GSE23806 were all assigned a TUMOR qualifier. No explicit assignment of a GSf or GSr phe-
notype for either GSC or GSE23806 samples was performed during the ComBat normalization procedure. All 
clustering and heatmap calculation was performed using heatmap.2 of the ‘R’ package “gplots”. For the clus-
tering of the full unified dataset including the TCGA tumor samples the top 100 genes for each tumor subset 
assignment were chosen from the full 840 gene signature (file TCGA_unified_CORE_ClaNC840.txt at https://
tcga-data.nci.nih.gov/docs/publications/gbm_exp/). Gene set enrichment analysis was based on MSigDB using 
the GSEA online tool18,19 hosted by the Broad Institute (http://www.broadinstitute.org/gsea/index.jsp). Overlap 
of genes differentially expressed between the two GSC sample groups and the Verhaak and colleagues GBM 
subtype signatures was determined manually in R because a detailed examination of the lists present in MSigDB 
(VERHAAK_GLIOBLASTOMA_*) revealed a large discordance with the gene/GBM-subtype association present 
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in the original file on the TCGA website (https://tcga-data.nci.nih.gov/docs/publications/gbm_exp/ TCGA_uni-
fied_CORE_ClaNC840.txt).
1H NMR spectroscopy. GSC 1D 1H NMR spectra were analyzed as previously described28. Briefly, cells 
were washed in PBS, centrifuged and suspended in PBS with 20% D2O and 2 mM Sodium 3-(TriMethyl-Silyl)
Propionate 2,2,3,3-d (TMSP) for a frequency standard. Cell suspension were inserted in a 1 mm NMR tube 
and centrifuged to obtain a final packed cell sample. NMR reagents were purchased from Cambridge Isotope 
Laboratories, Inc. (CIL Andover MA,USA).
1D and 2D COSY 1H NMR spectra were run at 400.14 MHz on a digital Avance spectrometer equipped with a 
1 mm microprobe (Bruker, AG, Darmstadt, Germany). Both 1D and 2D COSY spectra were acquired at T = 298 K. 
Water suppression in 1D and 2D 1H experiments was obtained using pre-saturation. The measurement of cell 
samples lasted approximately 210 min (60 min for the 1D experiment and 150 min for the 2D experiment).
NMR spectra were characterized by line widths in the range 9–15 Hz, which is typical of metabolite signals in 
intact cells and in the in vivo brain50. Chemical shifts were measured in cells with respect to Lactate methyl signal 
(Lac) at 1.33 ppm in 1D spectra and to Lac cross peak at 1.33–4.12 ppm in 2D COSY spectra. All NMR parameters 
were obtained in at least three independent experiments.
Metabolite signal assignments were performed according to indications from literature and by comparison 
with pure compounds.
1D peak deconvolution and integration as well as 2D COSY cross peak integration were performed by the 
WINNMR software (Bruker).
Individual integral values were normalized using the methyl group of cytosolic polypeptides at 0.94 ppm as 
internal reference for 1D spectra while for 2D spectra signal integrals were normalized to the intensity of the 
lysine cross-peak at 1.70–3.00 ppm.
Reverse-phase protein microarrays. RPPAs were performed as previously described35. Briefly, cell lysates 
were diluted with 2X Tris-Glycine SDS Sample Buffer (Life Technologies Corporation, Carlsbad, CA) prior to 
printing on nitrocellulose slides (Grace Bio-Labs, Bend, OR, USA) and were spotted in triplicate with the Aushon 
2470 contact pin arrayer (Aushon Bio Systems Inc., Billerica, MA), in 4-point two-fold dilution curves. Positive 
and negative expression control lysates were printed on every slide in a ten-point two-fold dilution curve. After 
incubation for 2 hours with I-Block (Life Technologies), array staining with antibodies was carried out on an auto-
mated slide stainer per manufacturer’s instructions (Autostainer CSA kit, DAKO, Carpinteria, CA). Biotinylated 
secondary antibody was either goat anti-rabbit IgG H + L (Vector Labs, Burlingame, CA) or anti-mouse (from 
CSA kit, DAKO). Streptavidin-conjugated IRDye680LT® (LI-COR Biosciences, Lincoln, NE, USA) was used as a 
final signal generating step. All antibodies used in these experiments are listed in Supplementary Table S2. Total 
protein concentration values were assessed by staining with Sypro Ruby Blot Stain (Life Technologies). Stained 
slides were scanned on a Tecan Power Scanner (Männedorf, Switzerland) equipped with a customized emission 
filter to increase efficiency in collection of IRDye680LT® fluorescence. Image analysis for spot recognition, quan-
tification and normalization was carried out using MicroVigene 5.1 software (Vigene Tech Inc., Carlisle, MA, 
USA).
Statistical analysis. For 1H NMR cluster analysis, agglomerative hierarchical clustering was performed uti-
lizing XLSTAT software, Addinsoft TM, version 2012.2.02. Values of log2 fold change (FC) resulting from the 
comparison between the two main clusters were calculated for each metabolite. Student’s t test was performed 
utilizing XLSTAT software, Addinsoft TM, version 2012.2.02.
RPPA data analysis was performed on standardized data using dedicated packages of the ‘R’ software (http://
www.r-project.org/, packages: Bioconductor, Heatplus, ggplot2, plyr, gplots, coin). Briefly, after local background 
correction, signal for secondary antibody staining alone was subtracted to raw antibody intensities for all spots 
and further normalization over the corresponding total protein staining allowed correction of potential loading 
biases. Standardized data were generated individually for each antibodies by subtracting the sample mean and 
dividing by the standard deviation (z scores). Wilcoxon rank sum test was used to compare RPPA data generated 
on our GSC lines while unpaired t test was used for statistical analysis of expression levels between P and M 
subtypes in TCGA level 3 RPPA data downloaded from http://gbm-biodp.nci.nih.gov. Statistical significance was 
accepted for p values lower than 0.05.
TCGA database bioinformatic analyses. In order to investigate GBM RNAseq and RPPA data from 
the TCGA project, we exploited ‘Next-Generation Clustered Heatmaps’ available at the Pan-Cancer NG-CHM 
Compendium website (http://bioinformatics.mdanderson.org/TCGA/NGCHMPortal/), hosted by the bioin-
formatics department of MD Anderson, University of Texas (Houston, TX, USA). Most of our results for the 
mRNA expression refer to the 3-Platform Aggregates used by Verhaak and colleagues8. To study the relationships 
between RPPA endpoints associated with GSf- and GSr-like clusters and patient outcome in TCGA data we used 
the GBM-BioDP software platform51 (http://gbm-biodp.nci.nih.gov). Briefly, based on (phospho-)proteins that 
resulted significantly modulated between GSr- and GSf-like GSC clusters in our RPPA analysis, we generated two 
lists of corresponding gene symbols (Supplementary Table S6) and we queried the GBM-BioDP web platform. 
For further analysis we selected only those RPPA endpoints shared between our analyses on GSCs and that per-
formed in the TCGA, either as total, phosphorylated or both. Thus, we evaluated whether the levels in P and M 
samples were in line or not with the RPPA levels measured in GSf-like versus GSr-like in our GSC samples 
(Supplementary Table S6). Methods used to compare RPPA levels between the P and M subtypes are described in 
the previous paragraph. The prognostic index for each patients was calculated as the sum of the products of the 
linear components of the Cox model and the corresponding RPPA values of the endpoints included as covariates 
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in the full model (Fig. 5B,D). Survival analysis in Fig. 6 was performed on TCGA data downloaded directly via 
‘TCGA Data Matrix’ (http://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm) and using as event variable either 
‘days to death’ for deceased patients or the maximum follow-up time for all other patients. Briefly, stratification 
of TCGA patients in either the GSf- or the GSr-like group was done by applying RPPA expression cut-offs for 
selected endpoint combinations. To this end we decided to use a subset of RPPA analytes differentially expressed 
between P and M subtypes or statistically significant covariates (p < 0.05) in single or combined Cox model done 
either on the full cohort of patients or on P and M subtypes, i.e. EGFR pY1173, RPS6 pS235-36, HER3 pY1289, 
SRC and SRC pY527. Based on this subset of RPPA endpoints, we tested all possible binary combinations of GSf- 
and GSr-like analytes using median expression level cut-offs, e.g. patients having expression values above the 
median for either SRC or SRC pY527 or HER3 pY1289 and simultaneous lower than median levels of either RPS6 
pS235-36 or EGFR pY1173 were assigned the GSF-like group while patients with opposite pattern were consid-
ered as GSr-like. Survival and prognostic index analyses have been performed by means of the survival package of 
the ‘R’ software. The results shown in the present manuscript are in part based upon data generated by the TCGA 
Research Network (http://cancergenome.nih.gov/).
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